Navigation Links
Intra-Cellular Therapies Announces Closing of $60 Million Private Placement and Completion of Reverse Merger
Date:9/3/2013

NEW YORK, Sept. 3, 2013 /PRNewswire/ -- Intra-Cellular Therapies, Inc. ("ITI" or the "Company"), a biopharmaceutical company focused on the development of therapeutics for CNS disorders, announced that it completed a private placement of approximately 18.9 million shares of its common stock to new and existing investors that resulted in gross proceeds of approximately $60 million to the Company, including approximately $15.3 million in bridge notes that converted into common stock at the closing. New institutional investors included Deerfield Management, Broadfin Capital and other leading healthcare investors. Leerink Swann LLC acted as lead placement agent for the transaction, and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. acted as the Company's legal counsel. Proceeds from the private placement will be used for the development of the Company's drug candidates including its lead drug candidate, ITI-007, which is being studied in a Phase II clinical trial for the treatment of schizophrenia.

Sharon Mates, CEO and Chairman of ITI, stated, "We are pleased to be able to close this private placement with such a leading group of institutional healthcare investors.  To date, ITI-007 has demonstrated clinical signs consistent with antipsychotic activity in patients with schizophrenia and its unique pharmacology may expand its therapeutic use beyond the treatment of acutely exacerbated schizophrenia to also include chronic residual schizophrenia by improving negative symptoms, mood, sleep and cognition.  We expect the proceeds from the financing will allow us to move forward with the clinical development of ITI-007 as a treatment for schizophrenia as well as other psychiatric and behavioral disorders."

Immediately following the private placement, ITI became a public reporting company by executing a reverse merger with a public shell company with no prior business operations. 
'/>"/>

SOURCE Intra-Cellular Therapies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Intra-Cellular Therapies Announces Completion of Phase I Single Rising Dose Trial of First-in-Class Selective Phosphodiesterase 1 (PDE1) Inhibitor and Reports Top-line Safety and Pharmacokinetic Findings
2. Syndax Pharmaceuticals Secures $26.6 Million Series B Financing for Advancement of Epigenetic Therapies for Treatment-Resistant Cancers
3. The Dyslipidemia Market Will Grow to $31 Billion in 2022, Driven by the Launch of Novel Therapies
4. Up to Sixty Percent of Surveyed U.S. Managed Care Organization Directors Expect to Cover Key Emerging Therapies for Parkinsons Disease on Their Largest Commercial Plan
5. CSL Biotherapies initiates shipments of its seasonal influenza vaccine to U.S. customers
6. MCOs Shifting Control Over Office-Administered Products from Medical to Pharmacy Benefit, Particularly Affecting Rheumatoid Arthritis Therapies
7. The Launch of Three New Parkinsons Disease Therapies Through 2015 Will Help Offset Market Losses Resulting from the Growing Impact of Generics
8. Statins Market to 2018 - Weak Product Pipeline and Shift of Focus towards Combination Therapies will Lead to Erosion of Brand Share
9. NGM Biopharmaceuticals Secures $50 Million in Series C Financing to Advance its Portfolio of Novel Therapies for Diabetes and Obesity
10. In Terms of Effect on Overall Survival, Current and Emerging Therapies Have No Advantage Over Avastin/FOLFIRI in the Treatment of Second-Line Metastatic Colorectal Cancer, According to Clinical Data and Thought Leader Opinion
11. Tafinlar in Combination with Mekinist and Nivolumab Have Considerable Efficacy and Tolerability Advantages Over Currently Used Therapies for the Treatment of Unresectable Malignant Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... -- PCCA received the Autism Hope Alliance,s (AHA) ... seal for best practices in meeting needs in ... materials and goods that meet strict criteria and ... by autism often have unique physical or psychological ... in food and medicine – for instance casein, ...
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/32cmct/inferior_vena ) ... Cava (IVC) Filters - Global Trends, Estimates and Forecasts, ... http://photos.prnewswire.com/prnh/20130307/600769 Global Inferior Vena ... million by 2016. The North America ... value while Europe claims approximately ...
(Date:12/15/2014)... Dec. 15, 2014  Inovio Pharmaceuticals, Inc. (NASDAQ: ... been added to the NASDAQ Biotechnology Index (NBI). ... become effective upon market open on December 22, ... designed to track the performance of a set ... biotechnology or pharmaceutical according to the Industry Classification ...
Breaking Medicine Technology:Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 2Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 4Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 2Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 3Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 4
... 18, 2011 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the ... advanced in-vitro diagnostic ("IVD") company, today announced the filing ... fiscal year ended March 31, 2011 with the U.S. ... which contains its audited consolidated financial statements for the ...
... Science, public health, and regulatory highlights from the ... document is designed for credentialed journalists. Release dates and times ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) FDA ... actions due to legal limitations. Events ...
Cached Medicine Technology:China Medical Technologies Announces the Filing of its Annual Report on Form 20-F for the Fiscal Year Ended March 31, 2011 with the SEC 2FDA News & Notes - Week of July 18, 2011 2FDA News & Notes - Week of July 18, 2011 3FDA News & Notes - Week of July 18, 2011 4
(Date:12/19/2014)... Consilium Staffing, Your Partner in ... for Federal Health Professionals annual meeting in Washington, ... military and federal healthcare providers. , In ... Business Engagement (NVSBE) conference last week in Atlanta, ... vital solution in addressing our nation’s shortage of ...
(Date:12/19/2014)... 2014 (HealthDay News) -- A new study suggests a ... severe hot flashes and night sweats -- and higher ... flashes are common during menopause, affecting about 60 percent ... women after menopause, since they then face a higher ... suggest women who exhibit moderate or severe menopausal symptoms ...
(Date:12/19/2014)... Randy Dotinga ... News) -- Common painkillers, including ibuprofen, might slightly reduce ... researchers say. Use of ibuprofen (Advil, Motrin) and ... cell skin cancer by 15 percent, the researchers concluded ... is usually caused by sun exposure. ...
(Date:12/19/2014)... HealthDay Reporter THURSDAY, Dec. 18, 2014 (HealthDay ... at least 20 seconds you may be at risk of ... leg may indicate that small strokes or tiny bleeds have ... is high, the investigators reported online Dec. 18 in the ... on one leg, as well as problems walking, should receive ...
(Date:12/17/2014)... 17, 2014 Unidesk Corporation today ... (ACOM), which welcomed its inaugural class in August ... to seamlessly support bring your own device (BYOD) ... – experience. The solution, comprised of Citrix ... Dell server and storage infrastructure and ...
Breaking Medicine News(10 mins):Health News:Consilium Staffing Increasing Awareness of Locum Tenens through Conference Appearances 2Health News:Severe Hot Flashes During Menopause May Raise Hip Fracture Risk Later: Study 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 3Health News:Can You Balance on One Leg? You May Have Lower Stroke Risk 2Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 2Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 3
... linked with contact lens wearers, seems to be on rise ... are unturned in combating it. // The fungal infection is ... and has started spreading in America, according to foodconsumer.org. ... alert in collaboration with the New Jersey Department of Health ...
... The percentage of Americans suffering from stroke is on the ... their risk of a stroke by clearing plaque from neck ... memory and mental skills. ,The findings of the ... further trials have to confirm the results. Then the procedure ...
... New Delhi: Sudoku, the new-age avatar of the ubiquitous crossword ... ,"Starting next week, Airtel will introduce this popular puzzle ... be the first to be available on any mobile phone ... one of India's leading providers for telecom services. ...
... Primal Scream has had a fascinating journey and as they wrap ... Riot City Blues, it is time for introspection for Bobby Gillespie. ... early 90s. // ,But after that there was a time ... was then that the "heroin hell" kicked in and it was ...
... Rifles said that they seized 16000 Indian chickens from border ... Rajshahi which were later burned due to the fear of ... following the outbreak of bird flu in India. Officials of ... outbreak of the H5N1 virus. Health ministry official said ...
... out guidelines that through NHS it would stop alluring health ... places the people are desperate and are attracted by the ... doctors, nurses and other health professionals from filling the many ... a strict surveillance regarding the issue and put an end ...
Cached Medicine News:Health News:Neck Artery Treatment Apart From Clearing Plaques Boosts Memory 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: